Co-Diagnostics, Inc. Common Stock
CODXCo-Diagnostics, Inc. (CODX) is a molecular diagnostics company specializing in the development and commercialization of innovative, cost-effective diagnostic tests. The company is known for its proprietary technology platform, Logix, which enables rapid design and production of PCR-based tests for infectious diseases, including COVID-19. Co-Diagnostics focuses on providing reliable diagnostic solutions for healthcare, agriculture, and animal health markets worldwide.
Company News
Following the WHO's declaration of a Public Health Emergency for the Bundibugyo virus Ebola outbreak on May 17, 2026, biodefense diagnostics companies are experiencing significant capital inflows. Co-Diagnostics is positioned as a strategic play due to its decentralized manufacturing network through joint ventures in India (CoSara) and Saudi Arab...
Co-Diagnostics (NASDAQ: CODX) reported full year 2025 results with revenue of $0.6 million versus $3.9 million in 2024, primarily due to lower grant revenue. The company posted a net loss of $46.9 million ($35.25 per share) compared to $37.6 million in 2024, driven by an $18.9 million non-cash impairment charge on intangible assets. Cash reserves...
Co-Diagnostics (NASDAQ: CODX) has shipped PCR Pro instruments and TB test kits to its joint venture CoSara Diagnostics in India to begin clinical performance studies. The company's PCR platform and TB test design align with new WHO recommendations for near-point-of-care molecular testing using tongue swab samples, positioning Co-Dx favorably for ...
Co-Diagnostics Inc. (NASDAQ: CODX) announced a 1-for-30 reverse stock split effective January 2, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split was approved by stockholders on December 5, 2025, and the stock will continue trading under the symbol 'CODX' on a split-adjusted basis.
Co-Diagnostics' joint venture CoSara will participate in VIROCON 2025, presenting ongoing preclinical studies for tuberculosis and HPV tests on their PCR point-of-care platform, with promising early results supporting advancement to clinical performance testing.
Related Companies
